jRCT2080223890已完成2 期
Effects of adrenomedullin in biologics-resistant patients with Crohn disease: randomized, double-blind, placebo-controlled phase 2a clinical trial
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, Randomized, Double-blind, Placebo-controlled Study
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Biologics-resistant patients against maintenance therapy of biologics
排除标准
- •Non-responder for biologics
- •Patients with small intestinal lesion and having risk of ileus
- •Patient with fulminant Crohn disease(CD)
- •Patient need early operation for CD
- •Patient with active infection
- •Patient with severe complication(s)
- •Patient with malignancy or past history of malignancy
- •Pregnant woman
结局指标
主要结局
-
efficacy change of CDAI at week 8
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase 2a clinical trial for ulcerative colitis using adrenomedullinulcerative colitisjRCT2080225159University of Miyazaki32
已完成
2 期
Phase II trial in treatment of gastrointestinal fistulas with endoscopic injection of an alpha-cyanoacrylate monomerGastrointetinal fistulasJPRN-UMIN000018486Second Department of Surgery, Wakayama Medical University, School of Medicine20
撤回
不适用
Clinical trial for amelioration of bowel uptake in PET/CTNeoplasmsKCT0001162Seoul National University Bundang Hospital300
进行中（未招募）
不适用
Phase II clinical trial exploring the activity of crizotinib in patients with advanced solid tumors induced by causal alterations of specific receptors (ALK and MET/HGF receptor tyrosine kinases) expressed by cancer sells.ocally advanced and/or metastatic malignant tumor (anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, papillary renal cell carcinoma type 1, alveolar soft part sarcoma, clear cell sarcoma or alveolar rhabdomyosarcoma) deemed incurable by conventional surgery, radiotherapy, systemic therapy or any other meansMedDRA version: 15.1Level: LLTClassification code 10065867Term: Alveolar rhabdomyosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10002227Term: Anaplastic large cell lymphoma T- and null-cell typesSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: PTClassification code 10001882Term: Alveolar soft part sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001988-52-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER582
进行中（未招募）
不适用
Cabozantinib in patients previously treated with immune checkpoint inhibitorsNeoplasmsKCT0005238Asan Medical Center48